Informa Pharma Intelligence releases Citeline's next generations of Sitetrove, Trialtrove and new API solutions
The industry's most comprehensive clinical trial data and analysis, now delivered to better fit customers' individual needs and workflows
Summary: Informa Pharma Intelligence announces three major releases for its clinical R&D Intelligence suite. The same leading global intelligence trusted by thousands worldwide for over 35 years is now backed by even more powerful, cutting edge technology. These new solutions will allow users to go deeper with clinical trial research than ever before, and will offer new options to help users better integrate Citeline's leading content with their own data.
LONDON, June 19, 2017 (GLOBE NEWSWIRE) -- Informa Pharma Intelligence, the leading provider of drug, device, company, clinical trial, and market intelligence in the competitive pharma and medtech markets announces today the launch of its next generation of Citeline's Sitetrove and Trialtrove solutions, as well as new application programming interfaces (APIs) for Trials and Drugs. The new solutions are designed to deliver unparalleled access to Citeline's robust clinical trial intelligence with greater ease, speed and efficiency than ever before.
"Our next generation of clinical R&D Intelligence solutions are truly market driven," said Linda Blackerby, President of Informa Pharma Intelligence. "We have partnered with hundreds of customers to understand their data needs and workflows, and have developed our new Citeline platform and APIs based directly on their feedback."
The new Trialtrove and Sitetrove provides users with the ability to go even deeper with search criteria to make better and more well-informed critical decisions, gain competitive advantage, save costs on and optimize ROI for their clinical trials. The new APIs will also come with Informa's acclaimed Ask-the-Analyst service, connecting users with therapeutic expert analysts whose average response time to queries is 24 hours or less.
Informa's new Trials and Drugs APIs will enable users to search or stream information directly from Citeline's R&D Intelligence databases into their own systems and embed Informa's quality datasets directly into their own organization's data and workflows, minimizing duplicated effort and time spent acquiring and manipulating data.
"Clinical R&D professionals need to design strategies, develop protocols, plan and execute trials that are on budget and on time," said Nicola Marlin, Vice President of Product. "Our team of scientific analysts live and breathe the data universe to bring our customers a deep understanding of the current clinical trial landscape. The new Citeline platform and API solutions allow users to enjoy the same depth and breadth of specialized, high caliber content, delivered the way they want to better fit their need, internal solutions, and workflows."
"These new releases further reinforce our commitment to our customers to help them gain critical insights into the global clinical trial landscape, realize greater cost-savings and ROI as they develop on their clinical trial programs," stated Michael Hay, Head of Intelligence. "No other intelligence solution comes close."
Attendees at this week's DIA and BIO International conferences will get a sneak preview of these next generation solutions, which will begin launching to customers in July. Additional solutions including the next generation of Citeline's Pharmaprojects and additional APIs for Investigators and Sites are in development for launch later this year.
For more information, visit pharmaintelligence.informa.com.
About Informa Pharma Intelligence
Informa Pharma Intelligence powers a full suite of analysis products - Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Medtrack, Biomedtracker, Scrip, Pink Sheet and In Vivo - to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.
With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn't covered through the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com.
Citeline, part of Informa's Pharma Intelligence vertical, is the world's most comprehensive source of real-time R&D intelligence for the pharmaceutical industry, featuring an unmatched intelligence collection and enrichment of global clinical trials, clinical trial investigator profiles and drug development pipelines.
Citeline is the R&D Intelligence arm of Informa's Pharma Intelligence vertical, one of the world's leading providers of drug, device, company, clinical trial and market intelligence in the pharma and medtech markets. For more information, visit pharmaintelligence.informa.com.
T: (212) 652-5302
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Informa Business Intelligence via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
CP Kelco Appoints Jennifer Aspen Mason as Sr. Vice President, Global Innovation22.2.2018 20:00 | Pressemelding
ATLANTA, Feb. 22, 2018 (GLOBE NEWSWIRE) -- CP Kelco, a leading global producer of specialty hydrocolloid solutions, announced today that Jennifer Aspen Mason has joined its Executive Leadership Team as Senior Vice President, Global Innovation, reporting directly to CP Kelco President Didier Viala. A global executive with more than 20 years of industry experience, Mason has an extensive background leading science organizations with Fortune 100 companies. Most recently, she spent more than five years with Mars, Incorporated, where she served as Technology and Science Strategy Officer for all Mars segments. In her new role, Mason is responsible for leading CP Kelco's global research and development (R&D) function, including strategic innovation imperatives to drive the company's long-term growth, as well as oversight of technical teams focused on new product innovation, process R&D and research. "We are truly delighted to welcome Jennifer to our team, and will surely benefit from her glob
Leading the industry: Excel Dryer is the first hand dryer manufacturer to publish third-party, verified Environmental Product Declarations (EPDs)22.2.2018 16:00 | Pressemelding
High-speed, energy-efficient XLERATOR®, XLERATOReco® and ThinAir® Hand Dryers evaluated and proven to be sustainable EAST LONGMEADOW, Mass., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Excel Dryer, Inc., today announced that three of their hand dryers, the original, patented, high-speed, energy-efficient XLERATOR® Hand Dryer, the XLERATOReco® Hand Dryer and the ThinAir® Hand Dryer, were evaluated, and their environmental claims, substantiated with the publication of the hand dryer industry's first Environmental Product Declarations (EPDs) by UL Environment, a business division of Underwriters' Laboratories. An Environmental Product Declaration is a standardized way of quantifying the environmental impact of a product by studying the raw materials and energy consumption during its production, use and disposal. For buyers and specifiers, the EPDs are a disclosure tool that helps purchasers better understand a product's sustainable qualities and environmental repercussions so they can make more inf
Intrinsyc Technologies (TSX: ITC and OTC: ISYRF) debuts system on module and development kit powered by NXP i.MX 8M processor22.2.2018 15:00 | Pressemelding
Powerful Embedded Computing Solutions Optimized for Multimedia Applications VANCOUVER, British Columbia, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Intrinsyc Technologies Corporation (TSX:ITC) (OTC:ISYRF) ("Intrinsyc" or the "Company"), a leading provider of solutions for the development and production of embedded and Internet of Things ("IoT") products, today announced the availability of the Open-X(TM) 8M System on Module ("SOM") and Development Kit. Intrinsyc's Open-X(TM) 8M SOM incorporates the new 64-bit NXP i.MX 8M processor and is ideal for powering IoT devices ranging from consumer smart home appliances to industrial building automation products. Its ultra-compact (55mm x 35mm) size enables its use in a wide range of form factors. The feature-rich SOM, with its advanced video and audio features, is ideal for streaming video/audio devices, voice control applications, and human-machine interface solutions. It offers high quality video playback with full 4K UHD and HDR along with the highe
Danal Inc. Creates Largest and Best Global Mobile Identity Solution22.2.2018 14:00 | Pressemelding
On track to cover 3 Billion+ Consumers SAN JOSE, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Danal, Inc., a global leader in mobile identity and authentication services, today announced that customer demand is driving its expansion into Asia and LATAM. The company is expanding to eight countries in Asia and LATAM this year in addition to its continued expansion in Europe and UK - creating the largest and most comprehensive Mobile Network Operator (MNO) based identity solution in the market. It is on track to cover over 3 Billion consumers worldwide and support numerous Fortune 500 Enterprises in their endeavor to fight fraud, account takeovers, assuring reliable consumer authentication with best in class experiences, and help conform to regulatory compliance including GDPR, TCPA, KYC and AML. Danal is experiencing strong demand by global brands for the US, EU, and Asian markets - especially in the financial sector like banks, insurances, money remitters, payment processors and innovative
Valeritas Announces V-Go® Distribution Agreement in Italy with Movi SpA22.2.2018 13:00 | Pressemelding
BRIDGEWATER, N.J., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers patients with type 2 diabetes V-Go® Wearable Insulin Delivery device, a simple, affordable, all-in-one insulin delivery option that is worn like a patch and can eliminate the need for taking multiple daily shots, today announced it has signed an exclusive distribution agreement with Movi SpA ("Movi") for the commercialization of V-Go Wearable Insulin Delivery device in Italy. Under the terms of the agreement, Valeritas has granted Movi the rights to promote, market, and sell the Company's flagship product V-Go Wearable Insulin Delivery device to diabetes clinics and patients in Italy. "We are thrilled to have Movi as our partner, and our distribution agreement is a significant first step to expand market access for V-Go Wearable Insulin Delivery device outside of the United States," said John Timberlake, CEO and President of Valeritas. "Movi is a truste
SoftServe Appoints Alex Chubay as Chief Technology Officer22.2.2018 13:00 | Pressemelding
Chubay to Champion the Next Phase of Innovation and Growth at World-Class Digital Consultancy AUSTIN, Texas, Feb. 22, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading global digital authority and consulting company, today announces its appointment of Alex Chubay as Chief Technology Officer, effective immediately. Chubay will lead global IT functions and play a key role in shaping the company's technology capabilities and roadmap. He will be responsible for SoftServe's Centers of Excellence, comprising Experience Design, Solutions, Intelligent Enterprise, Critical Services, Digital Platforms; as well as research and development within the company. He will report to SoftServe's CEO, Chris Baker. "SoftServe has operated at the cutting edge of technology for a quarter century, and to continue that momentum - and most importantly to ensure our customers, partners, and associates are served well in the future - we are delighted to announce Alex Chubay's appointment as CTO," said Baker. "This ne
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom